您当前的位置: 首页 > 资源详情

Medicalxpress,1月13日,WHO recommends two new drugs to treat patients with COVID-19

编译者:YUTING发布时间:2022-1-26点击量:301 来源栏目:最新研究

The drug baricitinib (a type of drug known as a Janus kinase (JAK) inhibitor, also used to treat rheumatoid arthritis) is strongly recommended for patients with severe or critical COVID-19 in combination with corticosteroids, says a WHO Guideline Development Group of international experts in The BMJ today.

Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation, with no observed increase in adverse effects.

The WHO experts note that baricitinib has similar effects to other arthritis drugs called interleukin-6 (IL-6) inhibitors so, when both are available, they suggest choosing one based on cost, availability, and clinician experience. It is not recommended to use both drugs at the same time.

However, the experts advise against the use of two other JAK inhibitors (ruxolitinib and tofacitinib) for patients with severe or critical COVID-19 because low certainty evidence from small trials failed to show benefit and suggests a possible increase in serious side effects with tofacitinib.

In the same guideline update, WHO also makes a conditional recommendation for the use of the monoclonal antibody sotrovimab in patients with non-severe COVID-19, but only in those at highest risk of hospitalization, reflecting trivial benefits in those at lower risk.

A similar recommendation has been made by WHO for another monoclonal antibody drug (casirivimab-imdevimab). The experts also note that there were insufficient data to recommend one monoclonal antibody treatment over another—and they acknowledge that their effectiveness against new variants like omicron is still uncertain.

As such, they say guidelines for monoclonal antibodies will be updated when additional data become available.

提供服务:导出本资源
  1. 1 Nature,11月10日,Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility
  2. 2 11月10日_研究人员分析宿主基因对COVID-19严重程度和易感性的影响
  3. 3 11月11日_新冠药物Remestemcel-L二期临床的中期分析结果积极
  4. 4 11月11日_CDC呼吁制定通用口罩规定以减少新冠传播
  5. 5 SSRN,2月20日,Dynamics of the Latest 2019 Novel Coronavirus Disease Epidemic in China: A Descriptive Study
  6. 6 SSRN,2月20日,Mental Health Problems and Social Media Exposure During COVID-19 Outbreak
  7. 7 SSRN,2月20日,Evaluating Incidence and Impact Estimates of the Coronavirus Outbreak from Official and Non-Official Chinese Data Sources
  8. 8 SSRN,2月20日,Clinical Characteristics and Treatment of Patients Infected with COVID-19 in Shishou, China
  9. 9 Nature,11月10日,Mobility network models of COVID-19 explain inequities and inform reopening
  10. 10 1月27日_Nature报道中国新型冠状病毒最新研究进展:病毒传播速度有多快?
  1. 1 Phys.org,2月21日,Why natural killer cells react to COVID-19
  2. 2 ScienceDaily,2月18日,T-cell responses may help predict protection against SARS-CoV-2 infection in individuals with and without cancer
  3. 3 2月18日_研究发现伊维菌素对轻度至中度COVID-19无效
  4. 4 2月17日_抗磷脂自身抗体可使COVID-19患者出现血栓
  5. 5 2月21日_科学家合成SARS-CoV-2病毒颗粒并发现刺突蛋白的转换机制
  6. 6 2月16日_免疫细胞靶向的SARS-CoV-2蛋白会引发蝙蝠冠状病毒的反应
  7. 7 Sciencedaily,2月17日,Study strengthens case that vitamins cannot treat COVID-19
  8. 8 Medicalxpress,2月16日,Study suggests increased risk of mental health disorders after COVID-19 infection
  9. 9 2月17日_高水平雌激素和抗酸剂可降低COVID-19风险
  10. 10 2月17日_研究发现COVID-19疫苗可提供持久的保护以预防再感染

版权所有@2017中国科学院文献情报中心

制作维护:中国科学院文献情报中心信息系统部地址:北京中关村北四环西路33号邮政编号:100190